UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 14A

(Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a)

of the Securities Exchange Act of 1934

(Amendment No.)

 

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:

 

Preliminary Proxy Statement
Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
Definitive Additional Materials
Solicitation Material Pursuant to Rule 14a-11(c) or rule 14a-12

 

Elite Pharmaceuticals, Inc.

(Name of Registrant as Specified in its Charter)

 

 

 

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

 

Payment of Filing Fee (Check the appropriate box):

 

No fee required.
   
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
   
  1) Title of each class of securities to which transaction applies:
     
  2) Aggregate number of securities to which transaction applies:
     
  3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11:
     
  4) Proposed maximum aggregate value of transaction:
     
  5) Total fee paid:

 

Fee paid previously with preliminary materials.

 

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously.  Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
   
  (1) Amount Previously Paid:
     
  (2) Form, Schedule or Registration Statement No.:
     
  (3) Filing Party:
     
  (4) Date Filed:

 

 

 

 

 

  

ELITE PHARMACEUTICALS, INC.

165 Ludlow Avenue

Northvale, New Jersey 07647

 

 

SUPPLEMENT TO PROXY STATEMENT

FOR THE SPECIAL MEETING OF SHAREHOLDERS

TO BE HELD ON JUNE 23, 2020

 

To The Shareholders of Elite Pharmaceuticals, Inc.:

 

This supplement updates the Definitive Proxy Statement, dated April 29, 2020 (the “Proxy Statement”), previously furnished to Shareholders of Elite Pharmaceuticals, Inc., a Nevada corporation (the “Company”), in connection with the Company’s Special Meeting of Shareholders to be held on June 23, 2020 (the “Special Meeting”).

 

Explanatory Note

 

This supplement is being filed solely to correct a typo on the proxy card furnished to certain Shareholders which mistakenly stated in Proposal No. “1” that the number of shares of common stock the Company would be authorized to issue would increase to 1,445,000 shares rather than to 1,445,000,000 shares. The typo was on the proxy card mailed to record holders by our transfer agent, the proxy card distributed on behalf of the clients of Mediant, and on the website proxyvote.com available pursuant to an e-mail on behalf of the clients of Broadridge Financial Solutions.

 

Accordingly, the transfer agent and clients of Mediant will be furnishing all holders to whom they mailed the proxy materials a copy of this notice and a corrected proxy card. Shareholders who received electronic delivery by Broadridge or Mediant on behalf of their clients will receive an additional email that will include a link to Broadridge’s or Mediant’s respective website with the corrected information on those websites effective on May 12, 2020.

 

If you have already voted using the old proxy card, your vote will be counted on the proposal as set forth in the Proxy Statement. If you decide to vote using the corrected proxy card, your prior vote will be superseded.

 

The procedure for voting has not changed.

 

This supplement should be read in conjunction with the Proxy Statement.

 

Thank you for your cooperation and continued support.

 

  Sincerely,
   
 
   
  Nasrat Hakim
  President and Chief Executive Officer
  May 11, 2020